About Baronio Fund Opportunities Board Lab Directory Industry Partners Join PSRC Members Only
PSRC on Facebook PSRC on Instagram PSRC on Twitter PSRC on Youtube

Back to 2021 Virtual Presentations




With great advancements in cancer treatment, radiation induced fibrosis (RIF) is becoming an increasingly prevalent problem. Under the guidance of Hagey Laboratory’s Dr. Derrick Wan and Dr. Michael Longaker, Christopher Lavin @ChrisVannLavin and colleagues compared two administration routes of deferoxamine for the treatment of RIF in mice: a transdermal patch vs a direct injection. The patch, which utilizes reverse micelle encapsulation technology, reduced ROS production, improved dermal microvasculature, and provided more favorable extracellular matrix/biomechanical characteristics compared to the injection, although both were effective. Deferoxamine is proving to have great potential in treating RIF, and this study provides insight into optimal administration methods and timing relative to irradiation. Deferoxamine Transdermal Patch vs Injection in the Treatment of Radiation Induced Fibrosis Christopher V. Lavin, MS @ChrisVannLavin; Darren B. Abbas, MD @AbbasDarren; Evan J. Fahy, MB BCh BAO, MCh; Daniel K. Lee, MD; Michelle Griffin, MBChB, PhD; Nestor M. Diaz Deleon, BS; Shamik Mascharak, BS; Arash Momeni, MD @amomenimd; Geoffrey C. Gurtner, MD @GeoffreyGurtner; Michael T. Longaker, MD, MBA @LongakerLab; and Derrick C. Wan, MD

Back to 2021 Virtual Presentations